EVERGREEN THERAGNOSTICS

Evergreen Theragnostics is focused on improving the available options for cancer patients using radiopharmaceuticals. The company is engaged in Contract Development and Manufacturing (CDMO) services as well as drug discovery and commercialization of proprietary products.

Evergreen is headquartered in Springfield, NJ in a state-of-the-art GMP radiopharmaceutical facility. The company was founded in 2019 by a team that brings a strong track record in theragnostic radiopharmaceutical manufacturing and commercialization.

Round

LIFTT Investment

In portfolio: Q1 2024
Venture phase: Start up
LIFTT funding: 1 M$
Round: 1

LIFTT Project Manager

Aurora Castello

Press Release